ESR2
breast cancer
estrogen receptor beta
extracellular matrix
tumorigenesis
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2022
2022
Historique:
received:
11
04
2022
accepted:
09
05
2022
entrez:
20
6
2022
pubmed:
21
6
2022
medline:
21
6
2022
Statut:
epublish
Résumé
Estrogen receptors (ERs) have pivotal roles in the development and progression of triple-negative breast cancer (TNBC). Interactions among cancer cells and tumor microenvironment are orchestrated by the extracellular matrix that is rapidly emerging as prominent contributor of fundamental processes of breast cancer progression. Early studies have correlated ERβ expression in tumor sites with a more aggressive clinical outcome, however ERβ exact role in the progression of TNBC remains to be elucidated. Herein, we introduce the functional role of ERβ suppression following isolation of monoclonal cell populations of MDA-MB-231 breast cancer cells transfected with shRNA against human
Identifiants
pubmed: 35719919
doi: 10.3389/fonc.2022.917633
pmc: PMC9203970
doi:
Types de publication
Journal Article
Langues
eng
Pagination
917633Informations de copyright
Copyright © 2022 Piperigkou, Koutsandreas, Franchi, Zolota, Kletsas, Passi and Karamanos.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Cancer Chemother Pharmacol. 1989;24(3):148-54
pubmed: 2544306
Int J Dev Biol. 2010;54(5):887-96
pubmed: 19757378
Semin Cancer Biol. 2020 May;62:125-133
pubmed: 31401293
Biomed Res Int. 2015;2015:925703
pubmed: 25874233
Front Oncol. 2021 Apr 22;11:650453
pubmed: 33968752
Sci Rep. 2017 Jan 12;7:40138
pubmed: 28079144
Mol Oncol. 2018 Dec;12(12):2055-2071
pubmed: 30171816
Matrix Biol. 2016 Dec;56:4-23
pubmed: 27179695
Nat Rev Cancer. 2017 May;17(5):302-317
pubmed: 28303905
Trends Mol Med. 2008 May;14(5):199-209
pubmed: 18406208
Semin Cancer Biol. 2020 May;62:192-200
pubmed: 31518697
Matrix Biol. 2019 Jan;75-76:1-11
pubmed: 30130584
Cancers (Basel). 2020 Jun 05;12(6):
pubmed: 32516978
Curr Protoc Immunol. 2001 May;Chapter 7:Unit 7.28
pubmed: 18432839
Cancers (Basel). 2019 Nov 20;11(12):
pubmed: 31756933
Curr Opin Biotechnol. 2016 Aug;40:41-48
pubmed: 26938687
Oncotarget. 2017 Oct 17;8(55):94650-94665
pubmed: 29212256
Matrix Biol. 2019 Jan;75-76:220-259
pubmed: 29128506
Steroids. 2018 May;133:2-7
pubmed: 29155216
Front Oncol. 2020 Mar 12;10:280
pubmed: 32226772
Breast Cancer Res Treat. 2012 Nov;136(2):331-45
pubmed: 23073759
FEBS J. 2019 Aug;286(15):2830-2869
pubmed: 30908868
Cancer Res. 2010 Jun 1;70(11):4778-84
pubmed: 20484043
Biochim Biophys Acta. 2007 May;1773(5):642-52
pubmed: 16926057
Matrix Biol. 2017 Dec;64:94-111
pubmed: 28797712
Nature. 2012 Oct 4;490(7418):61-70
pubmed: 23000897
Nat Commun. 2018 Jul 30;9(1):2980
pubmed: 30061623
Cells. 2020 Sep 04;9(9):
pubmed: 32899718
Cancer Cell. 2012 Mar 20;21(3):309-22
pubmed: 22439926
Nat Rev Mol Cell Biol. 2005 Aug;6(8):622-34
pubmed: 16025097
Matrix Biol Plus. 2020 Jan 22;6-7:100024
pubmed: 33543022
FEBS J. 2021 Dec;288(24):6850-6912
pubmed: 33605520
Oncotarget. 2018 Sep 21;9(74):33912-33930
pubmed: 30338035
Cell Signal. 2018 Nov;51:99-109
pubmed: 30071291
Nucleic Acids Res. 2019 Jul 2;47(W1):W556-W560
pubmed: 31114875
PLoS One. 2010 Jan 15;5(1):e8726
pubmed: 20090950
Matrix Biol Plus. 2020 May 28;6-7:100038
pubmed: 33543032
Am J Physiol Cell Physiol. 2022 May 1;322(5):C825-C832
pubmed: 35294845
Dev Cell. 2002 Aug;3(2):259-70
pubmed: 12194856
Cancers (Basel). 2021 Mar 22;13(6):
pubmed: 33809973
BMC Cancer. 2021 Feb 10;21(1):149
pubmed: 33568081
Semin Cancer Biol. 2020 May;62:116-124
pubmed: 31310807
Trends Mol Med. 2021 Oct;27(10):1000-1013
pubmed: 34389240
Nat Commun. 2022 Jan 10;13(1):69
pubmed: 35013251
Semin Cancer Biol. 2018 Oct;52(Pt 1):56-73
pubmed: 28882552
BMC Cancer. 2014 Aug 23;14:609
pubmed: 25151367
Cells. 2020 Oct 08;9(10):
pubmed: 33050027
Nat Rev Mol Cell Biol. 2022 Feb;23(2):89-90
pubmed: 34887545
Cancers (Basel). 2021 Feb 09;13(4):
pubmed: 33572395
Cell Commun Signal. 2020 Apr 7;18(1):59
pubmed: 32264958
Front Genet. 2022 Jan 06;12:809600
pubmed: 35069702
Front Biosci (Landmark Ed). 2015 Jun 01;20(7):1144-63
pubmed: 25961550
Sci Rep. 2022 Jan 7;12(1):183
pubmed: 34997025
Front Oncol. 2020 Apr 30;10:452
pubmed: 32426267
Matrix Biol Plus. 2020 Jan 25;6-7:100026
pubmed: 33543024
Chem Rev. 2018 Sep 26;118(18):9152-9232
pubmed: 30204432
Nat Rev Cancer. 2011 Jul 22;11(8):597-608
pubmed: 21779010
Biochim Biophys Acta. 2008 Mar;1778(3):660-9
pubmed: 17854762
Breast Cancer Res Treat. 2021 Jan;185(2):281-292
pubmed: 33001337
Cancer Discov. 2022 Jan;12(1):31-46
pubmed: 35022204
Proc Natl Acad Sci U S A. 1996 Jun 11;93(12):5925-30
pubmed: 8650195
Cells Tissues Organs. 2013;197(6):435-44
pubmed: 23774741
Oncogene. 2014 Mar 27;33(13):1649-57
pubmed: 23624917
IUBMB Life. 2022 Mar 8;:
pubmed: 35261139
Genes Dev. 2006 Dec 1;20(23):3199-214
pubmed: 17158740
FEBS J. 2022 Mar;289(6):1552-1574
pubmed: 34665934